New Research Reports

We maintain our BUY recommendation on the stock.

We maintain our HOLD rating on the stock.

DCB Bank's NIM declined by 9bps QoQ to 3.2% led by decline in yield on assets. Management targets improvement in NIMs to 3.2% with 20% liability book growth planned. Asset quality remain stable with GNPA at 2.98% vs 2.99% QoQ led by higher write offs. However, slippage ratio inched up led by stress in MFI and unsecured portfolio. Banks deposits growth remained strong at 20% YoY; credit growth too witnessed strong growth at 21% YoY. We expect 18% CAGR (FY25-27E) credit growth. NII grew by 17% YoY led by decline in margins. Core fee income grew by 18% Yoy; while one time gain during the quarter supported higher other income....

Birla Corporation (BCORP)’s 1QFY26 EBITDA increased ~34% YoY to INR3.5b (~8% miss due to lower-than-estimated realization). EBITDA/t was up ~23% YoY to INR725 (est. INR838), and OPM surged 2.3pp YoY to ~14% (est. ~16%).

We maintain our BUY recommendation on the stock

DCB Bank (DCBB) reported an 11% QoQ decline in PAT to INR1.57b (20% YoY growth, 10% miss) due to higher provisions in 1QFY26. NII grew 16.9% YoY/4% QoQ to INR5.8b (in line), while NIM contracted 9bp QoQ to 3.2%.

Restaurant Brands Asia (RBA) posted India revenue growth of 13% YoY (inline), led by a 14% YoY rise in store additions.

In line with our estimates, J Kumar’s Rs14.8bn/1.03bn Q1 revenue/PAT with ~15/19% y/y growth displays strong execution and improved margins.

Voltamp Transformers (VAMP) reported a soft operational performance in Q1FY26. Revenue and EBITDA declined by 1% and 4% while PAT remained flat on YoY basis buoyed by higher other income led by higher mark to market gains. VAMP clocked in sales volume of 3,260 MVA in Q1FY26 which is a decline of ~8% YoY in MVA terms. Voltamp has been a preferred vendor amongst its clients due to its prudent execution track record and working capital management despite the cyclical nature of the business. We believe growth will be soft over FY26 owing to capacity constraints. However, we expect significant pick up in volume...

Acutaas Chemicals registered a strong performance in Q1FY26. Revenue, EBITDA and PAT registered strong growth of 17%,73% and 218% respectively on YoY terms albeit from a weak base. We believe the company will can clock in revenue CAGR of 25-30% for the next 2 years with margins upwards of 23%. The growth will be propelled by strong growth in the advanced pharma intermediates business owing to strong traction in CDMO business and targeting of more molecules which will go off patent. We believe that strong traction in key molecules will continue along with further scale up of CDMO business with...